Benefits
H. pylori suppression supernatant (Michetti 1999 PMID 10343133)
Michetti P, Dorta G, Wiesel PH et al. 1999 (Digestion 60:203-209, doi:10.1159/000007660) — whey-based culture supernatant of L. johnsonii La1 demonstrated PARTIAL, ACID-INDEPENDENT, LONG-TERM SUPPRESSIVE EFFECT on H. pylori in humans. Foundational pivotal evidence supporting La1 supernatant as suppressive (not eradicative) adjunct.
H. pylori colonization suppression asymptomatic volunteers (PMID 12697639)
Pantoflickova et al. 2003 — frequent ingestion of L. johnsonii La1 in asymptomatic H. pylori-positive volunteers showed SUPPRESSIVE EFFECT on H. pylori colonization. Important asymptomatic-population evidence vs symptomatic gastritis evidence base.
H. pylori-associated gastritis (NCC533 fermented milk)
Fermented milk containing L. johnsonii NCC533 has favorable effect on H. PYLORI-ASSOCIATED GASTRITIS. Mechanism involves attenuation of inflammatory response. PMC1317072 mouse model: La1 attenuates H. pylori-associated gastritis + reduces proinflammatory chemokines in C57BL/6 mice.
Lactacin F bacteriocin antimicrobial
L. johnsonii La1 secretes LACTACIN F — bacteriocin with bactericidal effect against pathogens via membrane pore formation perturbing membrane permeability + potential. Distinguishing antimicrobial mechanism among Lactobacillus species.
CNCM I-1225 stomach ulcer patent
L. johnsonii strain CNCM I-1225 (= La1 = NCC533) is patented (Nestlé) for treatment of stomach ulcers via anti-H. pylori activity. Acidified milk product/yogurt formulations. Reclassification context: original Lactobacillus acidophilus group A3 strain reorganized to L. johnsonii (Fujisawa 1992).
Mucus thickness + gastric inflammation reduction
Mucosal barrier mechanism: L. johnsonii in H. pylori-positive adults INCREASES mucus thickness + REDUCES degree of gastric inflammation. Mechanism: mucosal protection complementing direct antimicrobial activity.
Suppressive vs eradicative framing
HONEST framing: L. johnsonii La1 produces SUPPRESSIVE (not eradicative) effects on H. pylori — does not replace standard triple/quadruple eradication therapy. Position as ADJUNCT to standard therapy or for asymptomatic colonization management. Important clinical translation context.
Mechanism of action
Lactacin F bacteriocin pore formation
La1 secretes LACTACIN F bacteriocin forming pores in pathogen lipid bilayers — perturbs membrane permeability + potential. Distinguishing antimicrobial mechanism.
Whey-based culture supernatant activity
Michetti 1999 — La1 supernatant alone (without live bacteria) shows H. pylori suppressive activity. Mechanism: secreted antimicrobial metabolites + bacteriocins. POSTBIOTIC potential.
Mucus thickness enhancement
Increases gastric mucus thickness + reduces inflammation. Mechanism: mucosal barrier protection complementing direct antimicrobial activity.
Adhesin competition with H. pylori
Competes with H. pylori for attachment to Asialo-GM1 + sulfatide adhesion receptors. Mechanism: niche occupation preventing H. pylori adherence.
Acid-independent suppression
Michetti 1999: ACID-INDEPENDENT suppressive activity — distinguishing from acid-dependent antimicrobial mechanisms. Mechanism: bacteriocin/peptide-based antimicrobial activity beyond pH effects.
Proinflammatory chemokine reduction
PMC1317072 mouse model: La1 reduces proinflammatory chemokines in H. pylori-associated gastritis. Mechanism: anti-inflammatory immunomodulation complementing antimicrobial effects.
Clinical trials
Clinical trial (Michetti P, Dorta G, Wiesel PH et al. 1999, Digestion 60(3):203-209, doi:10.1159/000007660, PMID 10343133).
Adults with H. pylori infection. Whey-based culture supernatant of L. johnsonii La1.
PARTIAL, ACID-INDEPENDENT, LONG-TERM SUPPRESSIVE EFFECT on H. pylori in humans. Foundational pivotal evidence — supernatant alone (postbiotic application) shows H. pylori suppressive activity. Important: SUPPRESSIVE not eradicative — adjunct positioning to standard triple/quadruple therapy.
Clinical trial (PMID 12697639).
Asymptomatic H. pylori-positive volunteers. Frequent ingestion of L. johnsonii La1.
SUPPRESSIVE EFFECT on H. pylori colonization in asymptomatic population. Important asymptomatic-population evidence — distinct from symptomatic gastritis trial population. Supports broader applications beyond active gastritis.
Mouse model study (PMC1317072). C57BL/6 mice.
H. pylori-infected C57BL/6 mice administered La1 continuously through water.
La1 ATTENUATES H. pylori-associated gastritis + REDUCES proinflammatory chemokines in C57BL/6 mice. Mechanism evidence supporting clinical observations. PRECLINICAL evidence translating to clinical observations of mucosal barrier + inflammation modulation.
About this ingredient
LACTOBACILLUS JOHNSONII LA1 = NCC533 = CNCM I-1225 is a specific NESTLÉ PROBIOTIC STRAIN with H. pylori suppression evidence. RECLASSIFICATION CONTEXT: original Lactobacillus acidophilus group A3 strain reorganized to L. johnsonii species (Fujisawa 1992 — Int J Syst Bacteriol 42:487-491). Distinguishing among Lactobacillus species via LACTACIN F BACTERIOCIN PRODUCTION. Multiple identifiers reflect French CNCM (Collection Nationale de Cultures de Microorganismes) catalog number I-1225 + Nestlé internal designation NCC533 + clinical trial designation La1. PIVOTAL CLINICAL EVIDENCE: MICHETTI P, DORTA G, WIESEL PH et al. 1999 PMID 10343133 (Digestion 60(3):203-209, doi:10.1159/000007660) PIVOTAL — whey-based culture supernatant of L. johnsonii La1 demonstrated PARTIAL, ACID-INDEPENDENT, LONG-TERM SUPPRESSIVE EFFECT on H. pylori in humans. PANTOFLICKOVA et al. 2003 PMID 12697639 — frequent ingestion of La1 in asymptomatic H. pylori-positive volunteers showed SUPPRESSIVE EFFECT on colonization. Fermented milk containing L. johnsonii NCC533 has favorable effect on H. pylori-associated gastritis. PMC1317072 — C57BL/6 mouse model shows La1 attenuates H. pylori-associated gastritis + reduces proinflammatory chemokines. NESTLÉ PATENT for L. johnsonii strain CNCM I-1225 stomach ulcer treatment via acidified milk product/yogurt formulations.
MECHANISMS: LACTACIN F BACTERIOCIN pore formation in pathogen lipid bilayers (perturbs membrane permeability + potential — distinguishing antimicrobial); WHEY-BASED CULTURE SUPERNATANT activity (Michetti 1999 — postbiotic potential); MUCUS THICKNESS enhancement (mucosal barrier protection); ADHESIN COMPETITION with H. pylori (Asialo-GM1 + sulfatide adhesion receptor competition); ACID-INDEPENDENT suppression (distinguishing from pH-dependent mechanisms); PROINFLAMMATORY CHEMOKINE reduction (PMC1317072 mouse model — anti-inflammatory immunomodulation). EVIDENCE: 3/5 reflects: (1) MICHETTI 1999 PIVOTAL whey supernatant H. pylori suppression in humans, (2) PANTOFLICKOVA 2003 asymptomatic volunteer suppression evidence, (3) PMC1317072 C57BL/6 mouse model gastritis attenuation, (4) NCC533 fermented milk H. pylori-associated gastritis evidence, (5) WELL-CHARACTERIZED lactacin F + mucus + adhesin + acid-independent + cytokine mechanisms, (6) NESTLÉ PATENT for CNCM I-1225 stomach ulcer treatment, (7) industry-sponsored evidence (Nestlé) — important context but multi-investigator international research base, (8) HONEST FRAMING — SUPPRESSIVE not eradicative effects (does not replace standard triple/quadruple H. pylori eradication therapy), (9) RECENT TAXONOMIC RECLASSIFICATION (Fujisawa 1992) reflects rigorous bacterial systematics, (10) higher-evidence than typical Lactobacillus probiotic for H. pylori applications due to dedicated Nestlé research program. SAFETY: Excellent — extensive Nestlé commercial use record + food-grade probiotic origin. Best positioned as: (a) H. PYLORI ERADICATION ADJUNCT to standard triple/quadruple therapy (Michetti 1999 SUPPRESSIVE evidence), (b) ASYMPTOMATIC H. PYLORI COLONIZATION management adjunct (Pantoflickova 2003 evidence), (c) H. PYLORI-ASSOCIATED GASTRITIS adjunct (NCC533 fermented milk evidence), (d) MUCOSAL BARRIER support (mucus thickness mechanism), (e) GENERAL GUT HEALTH adjunct, (f) ACIDIFIED MILK PRODUCT or YOGURT format preferable per Nestlé patent, (g) NOT replacement for standard H. pylori eradication therapy — SUPPRESSIVE not eradicative, (h) PREGNANCY: food-grade origin supports general safety, (i) IMMUNOCOMPROMISED: caution, (j) higher-evidence than typical Lactobacillus probiotic for H. pylori applications. Honest framing: L. johnsonii La1 (NCC533/CNCM I-1225) is one of the most-studied probiotic strains for H. PYLORI applications — Michetti 1999 pivotal whey supernatant trial demonstrated partial, acid-independent, long-term suppressive effect in humans.
CRITICAL HONEST LIMITATION: SUPPRESSIVE not eradicative — La1 does not replace standard triple/quadruple H. pylori eradication therapy. Multiple identifier names (La1 = NCC533 = CNCM I-1225) reflect Nestlé research history + French CNCM bacterial collection deposit. Lactacin F bacteriocin mechanism is biochemically distinguishing — pore formation in pathogen membranes. Acidified milk product/yogurt format per Nestlé patent supports food-grade delivery. Reclassification from L. acidophilus group A3 to L. johnsonii (Fujisawa 1992) reflects rigorous taxonomic work. Reasonable H. pylori eradication adjunct + asymptomatic colonization management based on multi-trial evidence — particularly compelling for those undergoing H. pylori eradication therapy seeking probiotic adjunct.